Integrated Health Center
of Inland Empire
of Inland Empire
Conventional medicine’s inability to effectively treat or cure cognitive decline is widely considered one of the largest failures of modern medicine. Alzheimer’s disease (AD) is still considered a degenerative and irreversible condition.
Early symptoms are often deemed “normal” signs of aging, and later symptoms are managed with ineffective pharmaceuticals, offering few options for hope or intervention.
In 2010, Alzheimer’s was the 6th leading “cause” of death in the US, and today, it has risen to 3rd place. Although hundreds of millions of dollars have been spent on research, there are no pharmaceuticals that effectively improve the prognosis of Alzheimer’s. Conventional health care has deemed Alzheimer’s a terminal illness brought on my bad genes or random bad luck.
The primary reason that so little progress has been made is that conventional health care focuses on symptoms. Without asking “what is the root of brain damage and its related symptoms,” there is no way to effectively recover from disease progression. While some pharmaceuticals may help silence or quiet cognitive decline symptoms, they do nothing to correct the underlying imbalances, exposures, and infections.
Also, conventional approaches are still tackling AD as mono-mechanistic. This means that there is an assumption that there is one cause of the disease and one effective way to combat it. In the case of Alzheimer’s, there is more than a singular mechanism causing this disease, so there must be more than one treatment. Research studies use animals that have been modified to develop Alzheimer’s, which is why some pharmaceuticals work on animals and fail miserably in human trials.
The third reason that Alzheimer’s treatment is so slow to progress is that much of the research is funded by pharmaceutical companies aimed at finding a treatment or cure that will result in big profits for corporate giants.
In fact, Eli Lilly put millions of dollars towards research to develop a drug that would break down amyloid plaque in the brain. The drug failed miserably in human trials and actually made patients much worse. Of the over 2,000 patients in the trial, all 2,000 progressed to end-stage Alzheimer’s disease.
The reason that this expensive and resource-rich approach is failing is that damage and irregularities in the brain ARE THE SYMPTOMS, not the cause. The key to treating AD is answering one critical question: WHY are these irregularities occurring?
For practitioners who are educated about lifestyle modification and who can offer counseling to their patients, genetic testing may be useful for prevention. However, this is rarely the case in conventional medicine.
Chronic diseases, which are predominant in health care today, are diseases that are a direct result of lifestyle and environmental exposure.
If research is clearly pointing to specific modifiable factors that may prevent, cause, or treat Alzheimer’s disease, why is the health care community still treating this as an incurable and terminal disease?